A molecule with a fifty year head start

Most of what shows up in a serum ingredients list is new. This one isn't.

Glycyl-L-histidyl-L-lysine, GHK for short, is a naturally occurring human tripeptide, discovered in blood plasma by Pickart and Thaler in 1973. That is not a typo. This molecule has been under active study since before the personal computer existed.

GHK has an unusually strong affinity for copper. Bind the two together and you get GHK-Cu, a copper complex that has spent five decades accumulating a genuinely wide evidence base: it promotes angiogenesis, raises skin oxygen levels, boosts the body's own antioxidant enzymes like superoxide dismutase, increases collagen production, and shows up in cosmetic formulations aimed at reducing wrinkles, redness, age spots and photodamage.

Copper itself is not a cosmetic ingredient dressed up to sound scientific. It is an essential trace element your body actually needs, a cofactor for haemoglobin synthesis, a component of mitochondrial and cytoplasmic enzyme systems, and specifically required for producing collagen and elastin, the two structural proteins that give skin its strength and bounce. GHK-Cu works, in large part, because it is not foreign machinery. It is the body's own repair signal, concentrated and delivered.

The problem nobody put on the label

Here is the part that does not make it into cosmetic marketing.

GHK-Cu is fragile. In diabetic and venous stasis skin ulcers, the kind of chronic wounds that refuse to heal, bacterial biofilms secrete powerful proteases, enzymes that chew through peptides in minutes. GHK-Cu applied to that environment gets broken down almost as fast as it arrives.

Inject it directly into wounded tissue instead, and a different problem shows up. It clears from the injection site rapidly, swept away by circulation before it has time to do the work it is capable of doing.

So the molecule is not the bottleneck. The molecule works, and has worked, reliably, for fifty years, in a controlled cosmetic setting where you can simply reapply it. The bottleneck is survival time in the one environment where speed actually matters: an open wound, hostile with enzymes built specifically to destroy peptides like this one.

That is a familiar shape of problem, if you read the retatrutide series in this publication. A molecule that does real biological work, undone by how fast the body clears it before it can finish. Retatrutide's answer was a fatty acid tail that binds to albumin and rides along in the bloodstream for days instead of minutes. This paper asks the same question about a completely different molecule, in a completely different setting, and arrives at a different engineering answer: wrap it.

What "wrap it" actually means

Liposomes are microscopic spheres built from the same class of fat molecules that make up your own cell membranes, arranged into a shell with the drug carried inside. They are not a new idea either. Doxorubicin and paclitaxel, two long-established cancer drugs, have both been delivered in liposomal form for years, specifically to concentrate the drug where it is needed and shield healthy tissue from it everywhere else.

Applied to skin, that same shell does something slightly different: it protects fragile cargo, like a peptide, from being destroyed before it can reach its target, and it can slow the rate at which the cargo leaves, extending how long it stays active in place.

A research group at Dalian Medical University took GHK-Cu, this fifty year old, already-commercialised molecule, and built it a liposomal shell. Then they tested whether that shell actually solved the survival problem, first in cells, and then in a real burn wound on a living animal.

Why this is worth reading carefully, not skimming

This is a smaller, earlier stage of evidence than the phase 3 diabetes trials covered elsewhere in this publication. It is a preclinical paper: cell culture experiments and a mouse model, not a human trial. That distinction matters, and this series will not blur it.

But the underlying question is a real one, and it sits exactly at the intersection of skincare and wound medicine that a lot of consumer products quietly straddle without ever being tested this directly. Does putting a well known, already-trusted ingredient inside a protective shell actually change what it can do, or is it packaging dressed up as innovation?

Part 2 opens the shell itself: what it is made of, how big it actually is, and the one measurement in this paper that complicates the simple story before you get too attached to it.

This series covers a peer-reviewed preclinical study conducted in cell culture and in mice. It has not been tested in humans for wound healing, and nothing here is medical advice or a product claim.